ArticleResearch and practice in thrombosis and haemostasis2026
A comprehensive assessment of the impact of COVID variant and vaccination on venous thromboembolism and mortality.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: COVID-19 is associated with increased mortality and morbidity. The mortality and adverse outcomes of current era COVID-19 variants have not been comprehensively studied. Objectives: To evaluate the association between COVID-19 variants and vaccination status on venous thromboembolism (VTE) and mortality rates, especially among recent strains, compared to a control group with acute respiratory infection (ARI). Methods: A retrospective cohort study was conducted using the National Clinical Cohort Collaborative database. Inclusion criteria were adult patients with COVID-19 or ARI between March 1, 2020 and November 1, 2024. Cohorts were balanced on demographics, prior healthcare visits, prior anticoagulation/antiplatelet use, COVID-19 vaccination and comorbidities. Primary outcomes were 30-day VTE and mortality using multivariable regression analysis. Kaplan-Meier survival curves were used to determine the duration of post-infectious VTE and mortality risk. Results: A total of 756,217 patients with COVID-19 and 678,747 with ARI were included. Patients with COVID-19 had an increased risk of VTE (odds ratio [OR]: 1.45) and mortality (OR: 1.80) compared to the ARI cohort. However, risk was attenuated later in the pandemic, with similar risk between patients with COVID-19 and ARI in the Contemporary Omicron period (May 2022-Nov 2024), especially among vaccinated individuals. Vaccination was associated with a reduced odds of VTE (OR: 0.41) and mortality (OR: 0.41). The post-COVID elevated VTE and mortality risk plateaued after 8 weeks. Conclusion: COVID-19 was associated with increased risk of 30-day VTE and mortality compared to ARI, but was no longer significantly different during the contemporary period (2022-2024) of the pandemic. COVID-19 vaccination was associated with reduced VTE events and mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.